文献速递消化内镜消化道肿瘤与早癌

食管内镜黏膜下剥离术后同日出院的安全性与可行性

Safety and feasibility of same-day discharge after esophageal endoscopic submucosal dissection.
PubMed 文献 · Gastrointest Endosc · 2020-07-25

这项回顾性队列研究纳入2017至2019年在梅奥诊所由单一内镜医师使用Clutch Cutter行食管内镜黏膜下剥离术的成人患者,评估同日出院的安全性。96例患者共140次ESD,85次同日出院、55次收治入院;同日出院者无术中或术后不良事件,作者认为对符合特定条件的患者同日出院安全可行。

要点

  • 96例患者共140次食管ESD,其中85次同日出院、55次收治入院。
  • 同日出院者未见术中或术后不良事件。
  • 入院者更常有抗血小板/抗凝用药史且美国麻醉医师学会评分更高,切除更大、手术时间更长。

核心结论

  • 食管ESD后同日出院安全可行;有经验的内镜医师可判断美国麻醉医师学会体能状态分级≤2、未接受抗血小板/抗凝治疗且术中无不良事件的患者是否可考虑同日出院。

研究设计与样本

  • 回顾性队列研究,纳入2017至2019年在梅奥诊所(美国明尼苏达州罗切斯特)由单一内镜医师使用Clutch Cutter装置(DP2618DT;Fujifilm)行相似食管ESD的成人患者。
  • 共96例患者(75%男性,平均年龄70±10.3岁),合计140次ESD,其中85次同日出院、55次收治入院。

主要发现

  • 55次入院中53次在24小时内出院,2次因与ESD操作无关的原因住院2至3天。
  • 入院者与同日出院者相比:抗血小板/抗凝用药史56.4% vs 34.1%(P = .01);平均美国麻醉医师学会评分3.2 vs 2.9(P = .007)。
  • 入院者切除标本更大(28.6 vs 20.1 mm;P < .0001),手术时间更长(103.4 vs 62分钟;P < .0001)。
  • 同日出院者中未见术中或术后不良事件。
  • 入院者中1例(1.8% vs 0%;P = .39)发生需内镜干预的术中出血,1例(1.8% vs 0%;P = .39)在ESD后24小时内出院前需输血,1例(1.8% vs 0%;P = .39)在7天内因切除边缘活动性出血需再住院并内镜干预。

关键数值与推荐

  • 主要终点为ESD后7天内的术后不良事件。

临床怎么用

  • 作者认为,有经验的内镜医师可判断美国麻醉医师学会体能状态分级≤2、未接受抗血小板/抗凝治疗且术中无不良事件的患者是否可考虑同日出院。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) is used for treating early luminal GI cancers. ESD is the standard of care in Asia, where it results in multiday admissions for observation. The goal of our study was to evaluate the safety and feasibility of same-day discharge (SDD) after ESD. METHODS: This is a retrospective cohort study of adults who underwent similar esophageal ESD with a Clutch Cutter device (DP2618DT; Fujifilm) at the Mayo Clinic (Rochester, Minn, USA) from 2017 to 2019 with a single endoscopist. The primary end point was postprocedural adverse events within 7 days of ESD. RESULTS: Of 96 patients (75% male, mean age, 70 ± 10.3 years) undergoing a total of 140 ESDs, 85 were SDD versus 55 admissions. Of the 55 admits, 53 were discharged within 24 hours, whereas 2 were admitted for 2 to 3 days for reasons unrelated to the ESD procedure. Admissions were more likely to have a history of antiplatelet/anticoagulant use (56.4% vs 34.1%; P = .01) and higher mean American Society of Anesthesiologists (ASA) score (3.2 vs 2.9; P = .007). Admissions had larger resections (28.6 vs 20.1 mm; P < .0001) with longer procedural durations (103.4 vs 62 minutes; P < .0001). Among SDDs, no intraprocedural or postprocedural adverse events were seen. Among admissions, 1 (1.8% vs 0%; P = .39) experienced intraprocedural bleeding requiring endoscopic intervention, 1 required transfusion before discharge within 24 hours of ESD (1.8% vs 0%; P = .39), and 1 required rehospitalization and endoscopic intervention within 7 days to address an active bleed along the resection margin (1.8% vs 0%; P = .39). CONCLUSIONS: SDD after esophageal ESD is safe and feasible. An experienced endoscopist can determine if SDD can be considered in patients with ASA physical classification status ≤2 who undergo resections off antiplatelet/anticoagulant therapy and do not experience intraprocedural adverse events.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Hanada Y, Wang KK. Safety and feasibility of same-day discharge after esophageal endoscopic submucosal dissection. Gastrointest Endosc. 2020. PMID: 32721491. doi:10.1016/j.gie.2020.07.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。